Generic drug labeling, skinny labels and carve-outs

On June 4, 2026, the Supreme Court ruled 9 to 0 that a brand company's lawsuit had failed to plausibly allege that a generic maker encouraged doctors to infringe its patent, when the generic's label left the patented use out. The generic, icosapent ethyl, had been approved in 2020 for one condition, severe hypertriglyceridemia, while the brand's newer cardiovascular use was still under patent. "We decline to put generic manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct," the opinion¹ said.

Both the rock and the hard place are labeling rules. Federal law requires a generic's label to match the brand's, with narrow exceptions, and one exception lets the generic leave out uses still protected by patent. That combination produces the so-called skinny label. A separate line of cases, decided in 2011 and 2013, holds that because a generic cannot rewrite its own label, it generally cannot be sued under state law for failing to warn.

These rules decide what text arrives in the package insert of most prescriptions Americans fill, and when a cheaper version can launch at all.

The same-labeling rule

Congress wrote the requirement into the statute. A generic application must contain "information to show that the labeling proposed for the new drug is the same as the labeling approved for the listed drug," under 21 U.S.C. 355(j)(2)(A)(v)², except for changes approved through a suitability petition or because the products "are produced or distributed by different manufacturers."

FDA's rule, 21 CFR 314.94(a)(8)(iv)³, spells out which differences are allowed: "differences in expiration date, formulation, bioavailability, or pharmacokinetics, labeling revisions made to comply with current FDA labeling guidelines or other guidance, or omission of an indication or other aspect of labeling protected by patent or accorded exclusivity." A generic's tablets can look different, use different inactive ingredients and carry its own company name, which is why your pill can change color between refills. The clinical content, from indications to warnings, follows the brand. Our comparison of generic and brand drugs goes through the rest.

Sameness applies before and after approval. FDA may refuse to approve a generic whose proposed labeling is not the same as the brand's, under 21 CFR 314.127(a)(7)⁴. After approval, 21 CFR 314.150(b)(10)⁵ lets FDA withdraw approval if the generic's labeling "is no longer consistent with that for the listed drug," apart from differences FDA approved or later patent and exclusivity carve-outs. When the brand updates its label, generics are expected to follow.

How section viii carve-outs work

A generic applicant has to answer every patent listed for the brand in FDA's Orange Book. For compound and formulation patents, the answer is a certification, often a Paragraph IV challenge. For a method-of-use patent there is another option. Under section 505(j)(2)(A)(viii) of the statute, the applicant can file "a statement that the method of use patent does not claim such a use" and leave the patented indication off its label. No lawsuit or 30-month stay follows from that statement alone.

A carve-out depends on how the brand describes its patent. Each listed method-of-use patent gets a use code, a short description the brand supplies. According to a 2012 Supreme Court decision⁸, FDA "does not attempt to verify the accuracy of the use codes" and will not approve a section viii carve-out "if the proposed label overlaps at all with the brand's use code." The Court held unanimously that a generic applicant sued for infringement may use a counterclaim to force correction of a use code that inaccurately describes the brand's patent as covering a particular method of using a drug.

Skinny labels are common. A 2021 study in JAMA Internal Medicine¹⁰ identified 56 brand drugs that first faced generic competition from 2015 to 2019 and were susceptible to skinny labeling; 24 of them, or 43 percent, had generic versions with skinny labels. The carved-out content covered method-of-use patents for nine drugs, orphan drug indications for eight and new patient populations, such as children, for six. The median time from the skinny-label approval to expiration of the protection that had been carved out was 3.2 years.

The skinny-label lawsuits

Carving out a use from the label does not stop doctors from prescribing the generic for it. The 2026 opinion noted that all 50 states and the District of Columbia have laws that permit or require pharmacists to substitute generics, and an AB rating tells them the products are interchangeable. Brand companies have argued that generic makers who know this, and who market their products as equivalents, are inducing infringement of the carved-out use.

That argument won in a case over carvedilol. The beta-blocker's generic launched in 2007 with a section viii statement and a label that omitted a patented use, "decreasing mortality caused by congestive heart failure." On Aug. 5, 2021, the Federal Circuit⁹ reinstated a jury verdict of induced infringement and a damages award of $234.1 million in lost profits and $1.4 million in reasonable royalties, citing the generic's label and marketing materials.

In 2026 the Supreme Court reset the test. It said the Federal Circuit "has increasingly trained its focus on whether the relevant statements could be read by medical providers as instructions to infringe," and rejected that approach: "the key question is whether a defendant actively encouraged infringement through its statements, not merely how others may understand those statements." Omissions, such as leaving a limitation of use off the label, cannot support liability, and calling a product a generic version of the brand is "normal industry practice." The Court also quoted the earlier circuit opinion's point that an AB rating means equivalence only "under the conditions specified in the generic's label." It sent the case back to the lower courts.

Safety warnings generics cannot change on their own

Sameness also limits what a generic company can do when it learns of a new risk. Brand companies can strengthen a warning before FDA reviews the change, through what FDA calls a changes-being-effected supplement. In the 2011 decision⁶, involving metoclopramide, FDA told the Court that generic manufacturers could not use that process, or send letters to doctors with new warnings, to change their labels unilaterally. FDA said they could, and were required to, propose stronger warnings to the agency instead.

By 5 to 4, the justices held that state failure-to-warn claims against generic makers were preempted. "The question for 'impossibility' is whether the private party could independently do under federal law what state law requires of it," the majority wrote. A dissent pointed out that the decision "affects 75 percent of all prescription drugs dispensed in this country." In the 2013 decision⁷, involving the anti-inflammatory sulindac and a jury award of more than $21 million, the Court extended that reasoning to design-defect claims that turn on the adequacy of warnings, and rejected the idea that a generic maker could avoid the conflict by pulling its product from the market.

FDA tried to change the underlying rule. A November 2013 proposed rule¹¹ would have let generic application holders distribute revised safety labeling, on a temporary basis, ahead of FDA review, creating what FDA called "parity among application holders." FDA withdrew the proposal¹² on Dec. 14, 2018, "in light of concerns expressed by commenters and considerations regarding Agency resources," saying it would keep looking for ways to get new safety information to providers and patients.

So the label on a generic still changes when the brand's label changes or FDA requires a change. Skinny labels, and the patents that make them necessary, are a regular feature of patent-heavy brand drugs. The icosapent ethyl case now returns to the lower courts under the Supreme Court's narrower test, and future skinny-label suits will have to point to affirmative statements by the generic maker to survive a motion to dismiss; a carved-out label and an equivalence rating will not be enough on their own.